An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
|Articles|November 15, 2012
Health Law Has States Feeling Tense Over Deadline
Advertisement
DES MOINES — The days since President Obama won re-election have been marked by tension and angst in Republican-led states like Iowa, where Gov. Terry Branstad has waited until the last minute to decide whether to create a crucial tool for people to get medical coverage under Mr. Obama’s health care law.
“There has been a total blackout of information,” said State Senator Jack Hatch, a Democrat who vented his frustration at a news conference here this week. “We’re behind schedule, we’re at a disadvantage, and I don’t know what our governor’s plan is to reposition Iowa.”
Read the full story:
Source: The New York Times
Advertisement
Related to this article
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5